Exact Sciences Corporation (EXAS) Financials
EXAS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 6.5 billion | 3.3 billion |
2023-09-30 | 6.4 billion | 3.3 billion |
2023-06-30 | 6.4 billion | 3.3 billion |
2023-03-31 | 6.3 billion | 3.2 billion |
EXAS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 34.6 million | 58.6 million |
2023-09-30 | -826000 | 61.9 million |
2023-06-30 | 65.7 million | 18600 |
2023-03-31 | -67.6 million | 49.1 million |
EXAS Net Income
No data available :(
EXAS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 777.6 million | - | 190.4 million |
2023-09-30 | 734.4 million | - | 168.4 million |
2023-06-30 | 775.7 million | - | 168.5 million |
2023-03-31 | 698.6 million | - | 174.7 million |
EXAS Shares Outstanding
EXAS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 34.9 million | 114.9 million | 353.4 million | 57.6 million |
2023-09-30 | 25.2 million | 111.4 million | 217.4 million | 173.2 million |
2023-06-30 | 34.7 million | 104.1 million | 238.0 million | 176.5 million |
2023-03-31 | 29.4 million | 95.4 million | 217.3 million | 187.0 million |
EXAS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 646.9 million | 171.8 million |
2023-09-30 | 628.3 million | 168.5 million |
2023-06-30 | 622.1 million | 157.0 million |
2023-03-31 | 602.5 million | 156.9 million |
EXAS
Price: $59.76
52 week price:
Earnings Per Share: -1.13 USD
P/E Ratio: -39.52
Exchange: NCM
Sector: Healthcare
Industry: Diagnostics & Research
Volume: 953316
Ebitda: -23.0 millionMarket Capitalization: 11.4 billion